Drug-Eluting Stent Study Evaluating a New Technology in Patients with Symptomatic Ischemic Heart Disease due to Coronary Artery Blockage.

Trial Profile

Drug-Eluting Stent Study Evaluating a New Technology in Patients with Symptomatic Ischemic Heart Disease due to Coronary Artery Blockage.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2018

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders
  • Focus First in man; Therapeutic Use
  • Acronyms DIRECT; DIRECT I FIM; DIRECT-I
  • Sponsors Svelte Medical Systems
  • Most Recent Events

    • 11 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 23 May 2013 Final 6 and 12-month results were presented at the 2013 EuroPCR meeting and have been published in EuroIntervention, according a Svelte Medical Systems media release.
    • 30 Jan 2013 Positive 6-month results have been reported in a Svelte Medical Systems media release. Final 6-month data will be presented at a medical symposia later in 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top